Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Subcellular Localization and Activity of the Mitogen-activated Protein Kinase Kinase 7 (MKK7) γ Isoform are Regulated through Binding to the Phosphatase Calcineurin.

Gibson ES, Woolfrey KM, Li H, Hogan PG, Nemenoff RA, Heasley LE, Dell'Acqua ML.

Mol Pharmacol. 2018 Nov 7. pii: mol.118.113159. doi: 10.1124/mol.118.113159. [Epub ahead of print]

2.

Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.

Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, Aisner DL, Van Bokhoven A, Heasley LE, Hirsch FR, Camidge DR.

Clin Lung Cancer. 2018 Sep 7. pii: S1525-7304(18)30234-1. doi: 10.1016/j.cllc.2018.09.001. [Epub ahead of print]

PMID:
30297175
3.

A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.

Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Kenichi Suda, Jiang T, Zhou C, Heasley LE, Hirsch FR.

Clin Lung Cancer. 2018 Sep;19(5):450-456. doi: 10.1016/j.cllc.2018.06.004. Epub 2018 Jun 28.

PMID:
30146263
4.

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.

Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC.

Oncotarget. 2018 Jan 16;9(10):8823-8835. doi: 10.18632/oncotarget.24260. eCollection 2018 Feb 6.

5.
6.

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.

Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA.

Cancer Immunol Res. 2017 Sep;5(9):767-777. doi: 10.1158/2326-6066.CIR-16-0365. Epub 2017 Aug 17.

7.

Analysis of Drug Resistance Using Kinome-Wide Functional Screens.

Singleton KR, Earley KT, Heasley LE.

Methods Mol Biol. 2017;1636:163-177. doi: 10.1007/978-1-4939-7154-1_11.

PMID:
28730479
8.

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR.

Lung Cancer. 2017 Jul;109:1-8. doi: 10.1016/j.lungcan.2017.04.010. Epub 2017 Apr 19.

9.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC.

Cancer Res. 2017 Jul 1;77(13):3551-3563. doi: 10.1158/0008-5472.CAN-17-0109. Epub 2017 Apr 20.

10.

Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.

Ohm AM, Tan AC, Heasley LE, Reyland ME.

Oncogene. 2017 Jul 27;36(30):4370-4378. doi: 10.1038/onc.2017.27. Epub 2017 Apr 3.

11.

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.

Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS.

Clin Transl Sci. 2016 Dec;9(6):293-301. doi: 10.1111/cts.12413. Epub 2016 Oct 20.

12.

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.

Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC.

BMC Genomics. 2015;16 Suppl 12:S2. doi: 10.1186/1471-2164-16-S12-S2. Epub 2015 Dec 9.

13.

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE.

Cancer Res. 2015 Oct 15;75(20):4398-406. doi: 10.1158/0008-5472.CAN-15-0509. Epub 2015 Sep 10.

14.

Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.

Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC.

Bioinformatics. 2015 Dec 1;31(23):3799-806. doi: 10.1093/bioinformatics/btv427. Epub 2015 Jul 23.

15.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR.

J Thorac Oncol. 2015 Jul;10(7):1083-90. doi: 10.1097/JTO.0000000000000562.

16.

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.

Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S.

Clin Cancer Res. 2015 Oct 1;21(19):4356-64. doi: 10.1158/1078-0432.CCR-14-3357. Epub 2015 May 26.

17.

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.

Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE.

PLoS One. 2015 May 6;10(5):e0123600. doi: 10.1371/journal.pone.0123600. eCollection 2015.

18.

Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Marek LA, Hinz TK, von Mässenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE.

Mol Cancer Res. 2014 Oct;12(10):1460-9. doi: 10.1158/1541-7786.MCR-14-0038. Epub 2014 Jun 25.

19.

Hypoxia regulates alternative splicing of HIF and non-HIF target genes.

Sena JA, Wang L, Heasley LE, Hu CJ.

Mol Cancer Res. 2014 Sep;12(9):1233-43. doi: 10.1158/1541-7786.MCR-14-0149. Epub 2014 May 21.

20.

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC.

Bioinformatics. 2014 Sep 1;30(17):2393-8. doi: 10.1093/bioinformatics/btu323. Epub 2014 May 7.

21.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.

22.

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC.

PLoS One. 2013 Dec 13;8(12):e82236. doi: 10.1371/journal.pone.0082236. eCollection 2013.

23.

Heterotrimeric G-protein, Gα16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer.

Avasarala S, Bikkavilli RK, Van Scoyk M, Zhang W, Lapite A, Hostetter L, Byers JT, Heasley LE, Sohn JW, Winn RA.

PLoS One. 2013 Oct 18;8(10):e76895. doi: 10.1371/journal.pone.0076895. eCollection 2013.

24.

Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck.

Göke F, Bode M, Franzen A, Kirsten R, Goltz D, Göke A, Sharma R, Boehm D, Vogel W, Wagner P, Lengerke C, Kristiansen G, Kirfel J, Van Bremen T, Bootz F, Heasley LE, Schröck A, Perner S.

Mod Pathol. 2013 Oct;26(10):1298-306. doi: 10.1038/modpathol.2013.58. Epub 2013 Apr 26.

25.

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE.

Oncogenesis. 2013 Mar 25;2:e39. doi: 10.1038/oncsis.2013.4.

26.
27.

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.

Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Barón AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, Graham DK.

Oncogene. 2013 Jul 18;32(29):3420-31. doi: 10.1038/onc.2012.355. Epub 2012 Aug 13.

28.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR.

Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.

29.

Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Kono SA, Heasley LE, Doebele RC, Camidge DR.

Curr Cancer Drug Targets. 2012 Feb;12(2):107-23. Review.

30.

Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE.

Clin Cancer Res. 2011 Aug 1;17(15):5016-25. doi: 10.1158/1078-0432.CCR-11-0050. Epub 2011 Jun 14.

31.

Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.

Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, Reyland ME.

Cancer Res. 2011 Mar 15;71(6):2087-97. doi: 10.1158/0008-5472.CAN-10-1511. Epub 2011 Feb 18.

32.

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE.

PLoS One. 2010 Nov 29;5(11):e14117. doi: 10.1371/journal.pone.0014117.

33.

Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model.

Chen P, O'Neal JF, Ebelt ND, Cantrell MA, Mitra S, Nasrazadani A, Vandenbroek TL, Heasley LE, Van Den Berg CL.

PLoS One. 2010 May 3;5(5):e10443. doi: 10.1371/journal.pone.0010443.

34.

Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1.

Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, Keith RL, Simpson P, Nemenoff RA, Winn RA.

Neoplasia. 2010 Mar;12(3):244-53.

35.

The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.

Kono SA, Marshall ME, Ware KE, Heasley LE.

Drug Resist Updat. 2009 Aug-Oct;12(4-5):95-102. doi: 10.1016/j.drup.2009.05.001. Epub 2009 Jun 4. Review.

36.

Analysis of Wnt7a-stimulated JNK activity and cJun phosphorylation in non-small cell lung cancer cells.

Heasley LE, Winn RA.

Methods Mol Biol. 2008;468:187-96. doi: 10.1007/978-1-59745-249-6_14.

PMID:
19099255
37.

Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9.

Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, Nemenoff RA.

Mol Biol Cell. 2009 Feb;20(3):791-800. doi: 10.1091/mbc.E08-07-0732. Epub 2008 Nov 26.

38.

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.

Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA Jr, Heasley LE.

Mol Pharmacol. 2009 Jan;75(1):196-207. doi: 10.1124/mol.108.049544. Epub 2008 Oct 10.

39.

Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.

Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA.

Mol Pharmacol. 2008 Mar;73(3):709-17. Epub 2007 Nov 30.

40.

Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma.

Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT Jr, Heasley LE, Nemenoff RA.

J Biol Chem. 2006 Sep 15;281(37):26943-50. Epub 2006 Jul 11.

41.

JNK regulation of oncogenesis.

Heasley LE, Han SY.

Mol Cells. 2006 Apr 30;21(2):167-73. Review.

42.

Inhibited neurogenesis in JNK1-deficient embryonic stem cells.

Amura CR, Marek L, Winn RA, Heasley LE.

Mol Cell Biol. 2005 Dec;25(24):10791-802.

43.

Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo.

Abell AN, Rivera-Perez JA, Cuevas BD, Uhlik MT, Sather S, Johnson NL, Minton SK, Lauder JM, Winter-Vann AM, Nakamura K, Magnuson T, Vaillancourt RR, Heasley LE, Johnson GL.

Mol Cell Biol. 2005 Oct;25(20):8948-59.

44.

Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation.

Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, Van Scoyk M, Acosta H, Mirus J, Barry N, Bren-Mattison Y, Van Raay TJ, Nemenoff RA, Heasley LE.

J Biol Chem. 2005 May 20;280(20):19625-34. Epub 2005 Feb 10.

45.

Multiple signaling conduits regulate global differentiation-specific gene expression in PC12 cells.

Marek L, Levresse V, Amura C, Zentrich E, Van Putten V, Nemenoff RA, Heasley LE.

J Cell Physiol. 2004 Dec;201(3):459-69.

PMID:
15389548
46.
47.

Signalling in stem cells: meeting on signal transduction determining the fate of stem cells.

Heasley LE, Petersen BE.

EMBO Rep. 2004 Mar;5(3):241-4. Epub 2004 Feb 20. No abstract available.

48.
49.

gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth.

Winn RA, Bremnes RM, Bemis L, Franklin WA, Miller YE, Cool C, Heasley LE.

Oncogene. 2002 Oct 24;21(49):7497-506.

50.

Differential gene regulation by specific gain-of-function JNK1 proteins expressed in Swiss 3T3 fibroblasts.

Han SY, Kim SH, Heasley LE.

J Biol Chem. 2002 Dec 6;277(49):47167-74. Epub 2002 Sep 26.

Supplemental Content

Loading ...
Support Center